Biorithm, a Singapore-based women’s health MedTech, has closed $3.5 million in Series A funding, co-led by Adaptive Capital Partners and SEEDS Capital, investment arm of government agency Enterprise Singapore.

Biorithm said in a statement on Monday that the funding will be utilized to double down on expanding the reach of the firm’s connected pregnancy management solutions firstly across Southeast Asia and the United States.

To bolster its expansion blueprint, Biorithm is headquartered in two locations, with its regional headquarters in Singapore as a strategic hub for Southeast Asian expansion, and with Boston as its US headquarters.

Inherently attuned to how patient experience is a significant part of the pregnancy journey, Biorithm is also channeling its incoming funding into further research that demonstrates how remote care can be most effectively deployed.

Having successfully completed clinical trials with healthcare institutions in Singapore and the United Kingdom, Biorithm will be expanding its clinical trial footprint to more of its priority markets.

In its aim to strengthen the overall women’s health ecosystem, Biorithm will chart out and foster key partnerships with various stakeholders globally to improve maternal and baby health through data, personalized and accessible care.

“We feel a deep commitment to improving the health of expectant mothers and putting an end to preventable complications,” said Amrish Nair, Founder and Chief Executive Officer, Biorithm.

According to him, there is a collapse of maternal care driven by socio-economic factors and limitation of current monitoring technologies in many regions across the world, and the firm is hard at work to solve this problem in partnership with the wider health ecosystems at play.

“The investment we have received is a testament to our mission at Biorithm, and a future where every expectant mother has access to healthcare that is not only proactive but profoundly connected to her unique journey,” he added.

With a homegrown spirit and a global vision, Biorithm is dedicated to advancing pregnancy care by developing cutting-edge solutions for personalized connected maternity care.

The firm has developed a remote maternal-fetal care platform with novel intellectual property in device and algorithms.

Complications from childbirth result in mortality for 800 women every day, Biorithm said it is committed to ending preventable pregnancy complications by pioneering new standards of care through protocol-based remote monitoring of maternal and fetal biometrics.

Its Femom is a patient-friendly technology that facilitates patient monitoring, accessible personalized guidance, and seamless integration of predictive analytics that help clinicians to identify early signs of complication.

According to the statement, the funding from new investor, Adaptive Capital Partners, and existing investor SEEDS Capital cements their recognition of Biorithm’s pivotal role in reshaping the landscape of women’s healthcare through innovative technology.

“Building a system of connected medical care is crucial to help clinicians predict, diagnose, and formulate calculated decisions on early intervention to prevent complications and devise treatments,

“We are excited with our investment into Biorithm as the company is focused on creating measurable and actionable value in maternal health, integrating this system across all touchpoints to ensure safety throughout the pregnancy journey.” said Shi Ying, Founder and Managing Partner, Adaptive Capital Partners.

Tan Kaixin of SEEDS Capital said by leveraging technology to enable remote monitoring, Biorithm’s offering provides enhanced access to quality care for expectant mothers.

“We are excited to continue backing Biorithm as they accelerate their commercialization in the United States and support their vision of revolutionizing the global maternal health market,

“Investments in MedTech startups like Biorithm will propel the healthcare ecosystem to new heights,” Tan added.

As the investment arm of Enterprise Singapore, SEEDS Capital catalyses smart investments into innovative Singapore-based early-stage startups with strong intellectual content and global market potential.

The firm focuses its investments into emerging and strategic sectors aligned with national priorities, including manufacturing, trade and connectivity, human health and potential, urban solutions and sustainability, and smart nation and digital economy.

Adaptive Capital Partners is a Singapore based, early-stage technology focused venture capital firm.

The firm invests in high conviction and disruptive technology startups with a predominant focus in HealthTech and MedTech while working with founders in many of their defining challenges with the team’s deep experience as an operator and research background.

Supermom launches initiative to partner 25 Singaporean brands expanding to Indonesia